Type 2 endometrial cancer is associated with a high density of tumor-associated macrophages in the stromal compartment

Reproductive Sciences

Volumn 22, Issue 8, 2015, Pages 948-953

  Kelly, Michael G ^a   Francisco, Antonio M C ^b   Cimic, Adela ^a   Wofford, Anne ^a   Fitzgerald, Nora C ^a   Yu, Jie ^a   Taylor, Robert N ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDADE DO VALE DO SAPUCAÍ   (Brazil)

Author keywords

endometrial cancer; tumor microenvironment; tumor associated macrophages

Indexed keywords

CD163 ANTIGEN; CHLORDANE; CD68 ANTIGEN, HUMAN; CD86 ANTIGEN; CD86 PROTEIN, HUMAN; CELL SURFACE RECEPTOR; DIFFERENTIATION ANTIGEN; FIXATIVE; FORMALDEHYDE; LEUKOCYTE ANTIGEN; PARAFFIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CELL DENSITY; CLINICAL ARTICLE; ENDOMETRIUM CANCER; ENDOMETRIUM CANCER TYPE 2; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; OXIDATIVE STRESS; PRIORITY JOURNAL; STROMA; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; CELL COUNT; CLASSIFICATION; COMPARATIVE STUDY; ENDOMETRIUM; ENDOMETRIUM TUMOR; IMMUNOLOGY; MACROPHAGE; MIDDLE AGED; OBSERVER VARIATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROCEDURES; REPRODUCIBILITY; STROMA CELL; TISSUE FIXATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD86; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS, TUMOR; CELL COUNT; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; FIXATIVES; FORMALDEHYDE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MIDDLE AGED; OBSERVER VARIATION; PARAFFIN EMBEDDING; PHENOTYPE; PREDICTIVE VALUE OF TESTS; RECEPTORS, CELL SURFACE; REPRODUCIBILITY OF RESULTS; STROMAL CELLS; TISSUE FIXATION; TUMOR MICROENVIRONMENT;

EID: 84934332887     PISSN: 19337191     EISSN: 19337205     Source Type: Journal    
DOI: 10.1177/1933719115570912     Document Type: Article

References (26)

1. American Cancer Society Web site. http://www.cancer.org/acs/groups/cid/documents/webcontent/003097-pdf. Updated 2014. Accessed 2014.
2. Hao NB, Lü MH, Fan YH, Cao YL, Zhang ZR, Yang SM,. Macrophages in tumor microenvironments and the progression of tumors. Clin Dev Immunol. 2012; 2012: 948098.
3. Sica A, Mantovani A,. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012; 122 (3): 787-795.
4. Tang X,. Tumor-associated macrophages as potential diagnostic and prognostic biomarkers in breast cancer. Cancer Lett. 2013; 332 (1): 3-10.
5. Ong SM, Tan YC, Beretta O,. Macrophages in human colorectal cancer are pro-inflammatory and prime T cells towards an anti-tumor type 1 inflammatory response. Eur J Immunol. 2012; 42 (1): 89-100.
6. Espinosa I, Carnicer MJ, Catasus L,. Myometria invasion and lymph node metastases in endometrioid carcinomas: tumor-associated macrophages, microvessel density, and HIF1A have a crucial role. Am J Surg Pathol. 2010; 34 (11): 1708-1714.
7. Ohno S, Ohno Y, Suzuki N,. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004; 24 (5C): 3335-3342.
8. Dun EC, Hanley K, Wieser F, Bohman S, Yu J, Taylor RN., Infiltration of tumor-associated macrophages is increased in the epithelial and stromal compartments of endometrial carcinomas. Int J Gynecol Pathol. 2013; 32 (6): 576-584.
9. Akaike H,. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974; 19 (6): 716-723.
10. Vogel DY, Glim JE, Stavenuiter AW,. Human macrophage polarization in vitro: maturation and activation methods compared. Immunobiology. 2014; 219 (9): 695-703.
11. Medrek C, Ponten F, Jirstrom K, Leandersson K,. The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients. BMC Cancer. 2012; 12: 306.
12. Edin S, Wikberg ML, Dahlin AM,. The distribution of macrophages with a M1 or M2 phenotype in relation to prognosis and the molecular characteristics of colorectal cancer. PLOS One. 2012; 7 (10): e47045.
13. Sica A, Larghi P, Mancino A,. Macrophage polarization in tumour progression. Semin Cancer Biol. 2008;(18): 349-355.
14. Pikarsky E, Porat RM, Stein I,. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature. 2004; 431 (7007): 461.
15. Friedenreich CM, Langley AR, Speidel TP,. Case-control study of inflammatory markers and the risk of endometrial cancer. Eur J Cancer Prev. 2013; 22 (4): 374-379.
16. Wang T, Rohan TE, Gunter MJ,. A prospective study of inflammation markers and endometrial cancer risk in postmenopausal hormone nonusers. Cancer Epidemiol Biomarkers Prev. 2011; 20 (5): 971-977.
17. Dossus L, Lukanova A, Rinaldi S,. Hormonal, metabolic, and inflammatory profiles and endometrial cancer risk within the EPIC cohort-a factor analysis. Am J Epidemiol. 2013; 177 (8): 787-799.
18. Singer CF, Kronsteiner N, Marton E,. Interleukin-1 system and sex steroid receptor gene expression in human endometrial cancer. Gynecol Oncol. 2002; 85 (3): 423-430.
19. Slater M, Cooper M, Murphy CR,. Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma. Acta Histochem. 2006; 108 (1): 13-18.
20. Dumas G, Dufresne M, Asselin É Girouard J, Carrier C, Reyes-Moreno C,. CD40 pathway activation reveals dual function for macrophages in human endometrial cancer cell survival and invasion. Cancer Immunol Immunother. 2013; 62 (2): 273-283.
21. Guerra F, Kurelac I, Cormio A,. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet. 2011; 20 (12): 2394-2405.
22. Qian BZ, Pollard JW,. Macrophage diversity enhances tumor progression and metastases. Cell. 2010; 141 (1): 39-51.
23. Hanahan D, Christofori G, Naik P, Arbeit J,. Transgenic mouse models of tumor angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer. 1996; 32A (14): 2386.
24. Vaughan RA, Garcia-Smith R, Dorsey J, Griffith JK, Bisoffi M, Trujillo KA,. Tumor necrosis factor alpha induces Warburg-like metabolism and is reversed by anti-inflammatory curcumin in breast epithelial cells. Int J Cancer. 2013; 133 (10): 2504-2510.
25. Beranek JT,. CD68 is not a macrophage-specific antigen. Ann Rheum Dis. 2005; 64 (2): 342-343; author reply 343-344.
26. Ruffell B, Affara NI, Coussens LM,. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012; 33 (3): 119-126.